Combined detection of peripheral blood VEGF and inflammation biomarkers to evaluate the clinical response and prognostic prediction of non-operative ESCC

Abstract

An association between angiogenesis/inflammation status and tumor has been reported in various types of cancer. This study sought to assess the role of peripheral blood VEGF and some inflammation biomarkers in evaluating clinical response and prognosis in patients with non-operative esophageal squamous cell carcinoma (ESCC). Peripheral blood of 143 patients with non-operative ESCC at our institute was dynamically collected at 5 time points including 1 day before radiotherapy, during radiotherapy (15f), at the end of radiotherapy, 1 month after radiotherapy, and 3 months after radiotherapy. VEGF expression in the peripheral blood was detected and related inflammation biomarkers such as GPS, CAR and CLR were counted. Logistic regression and Cox regression were implemented respectively to analyze the correlation of each predictor with clinical response and prognosis. The performance of combined testing was estimated using AUCs. Based on independent predictors, a nomogram prediction model was established to predict the probabilities of 1- and 2-year PFS of patients. The effectiveness of the nomogram model was characterized by C-index, AUC, calibration curves and DCA. VEGF and CLR levels at the end of radiotherapy were independent predictors of clinical response, while VEGF and GPS levels at 3 months after radiotherapy were independent prognostic predictors. The efficacy of combined detection of VEGF and CLR is superior to the single detection in evaluating clinical response and prognosis. The nomogram showed excellent accuracy in predicting PFS. The combined detection of VEGF and CLR at the end of radiotherapy can be used to evaluate the clinical response of patients with non-operative ESCC, and the combined detection of VEGF and GPS 3 months after radiotherapy can be used to predict the prognosis. Implemented by nomogram model, it is expected to provide practical and reliable method to evaluate the clinical response and prognosis of patients with non-operative ESCC tool.

In Vitro and In Vivo Evaluation of a Cyclic LyP-1-Modified Nanosystem for Targeted Endostatin Delivery in a KYSE-30 Cell Xenograft Athymic Nude Mice Model

“…Angiogenesis is over-expressed in tumor progression, tumorigenesis and metastasis and widely validated for its activation in SCC [ 50 , 51 , 52 ]. VEGF is an angiogenesis marker [ 53 ] that is upregulated in SCC as proven from surgical samples of patients managed by curative surgery [ 54 ].…”

Inflammation-related parameter serve as prognostic biomarker in esophageal squamous cell carcinoma

“…Accumulating evidence from recent studies indicates that several inflammatory markers have predictive value in the prognosis of cancer. In clinical practice, the systemic inflammatory response is regarded as a low-cost, highly practicable biomarker, commonly evaluated via routine blood tests (leukocytes, neutrophils, lymphocytes, monocytes, platelets, et al) and blood biochemical indicators (albumin, C-reactive protein) (7). Inflammation-related parameters, including neutrophil-lymphocyte ratio (NLR), monocyte-lymphocyte ratio (MLR), platelet-lymphocyte ratio (PLR), and C-reactive protein/ albumin ratio (CRP/Alb), are associated with tumorigenesis and development and serve as independent prognostic factors for cancer.…”